CARPE DIEM Study: Cognition, Age and Rapamycin Effectiveness-Downregulation of the mTor Pathway
The purpose of this study is to evaluate if if the drug, Rapamycin, will reach the brain and effectively treat symptoms of Alzheimer’s disease and mild cognitive impairment using cerebrospinal fluid.
Eligibility: Adults, ages 55 to 85, diagnosed with mild cognitive impairment or early stages of Alzheimer’s disease
SToMP-AD Study: Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease Study
The purpose of this study is to evaluate if a combination of two medications may be an effective intervention for treating AD symptoms in future studies.
Eligibility: Adults, aged 65 years or older, with a diagnosis of Alzheimer’s disease